Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results…

By P. Bonomi, Kyungmann Kim, D. Fairclough, D. Cella, J. Kugler, E. Rowinsky, Michael Jiroutek, David H. Johnson. Journal of Clinical Oncology, 2000

615 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f55e5043023923aa58f2c57212918cc3e3ed89ab

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. David H. Johnson
2. C. Azzoli
3. Sherman Baker
4. Thomas J. Smith
5. J. Olak
6. W. Sause
7. John R. Strawn
8. D. Pfister

Citations in the corpus

• American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. (2004, background): “Much of the data suggest that the newer regimens provide higher response rates and longer survival times than single agent cisplatin, or first-generation cisplatinbased regimens [116-126].”